ClinicalTrials.gg
Not yet recruitingNCT06913218Updated Apr 6, 2025

A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically Resected PDAC

A Phase 1 interventional study of AK154 and Cadonilimab in Pancreas Cancer and Pancreas Cancer, Duct Cell Adenocarcinoma, sponsored by Akeso. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-04-06.

Sponsored by Akeso · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 630 studies in Pancreatic Neoplasms with a site in China — 334 open to participants now, 359 under way, 30 of them phase 3. Pancreatic Neoplasms · China.

Planned enrollment
236th of 508
60 · median 58
Started
2025
with 83 others
Phase 1
111 of 630
62 open now
Primary completion
2028-02
later than 297 of 358 live
Registered
498th of 630
by date

Among the 630 studies in Pancreatic Neoplasms with a site in China, this one is the 236th largest by planned enrollment of the 508 interventional ones that give a count, is one of 84 that started in 2025, is one of 111 in phase 1, reaches primary completion later than 297 of the 358 other live ones, and was the 498th registered.

Pancreatic Neoplasms

3,897 studies on the registry are indexed under Pancreatic Neoplasms; 1,002 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

334 of the 630 studies in Pancreatic Neoplasms with a site in China are open now. Recruiting first, the newest first:

329 more — sign in →

All 334 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 742 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 151 (20%) stop at 75 or younger; 40 take children under 18; 59 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 630 studies in Pancreatic Neoplasms with a site in China, or all of them as a file.
02

Study summary

To explore safety and efficacy of neoantigen personalized mRNA vaccines AK154 monotherapy or in combination with AK104/AK112 and sequential mFOLFIRINOX regime in Resected PDAC

Read the detailed description

This is a prospective, open-label, single-center, exploratory clinical study. To explore the safety, tolerability, efficacy, immunogenicity, and PK/PD profile of neoantigen personalized mRNA vaccine AK154 monotherapy or combined with AK104 or AK112, sequential mFOLFIRINOX chemotherapy regimen as postoperative adjuvant therapy in Surgically Resected Pancreatic Adenocarcino

03

Conditions studied

  • Pancreas Cancer
  • Pancreas Cancer, Duct Cell Adenocarcinoma

Keywords

  • adjuvant
  • pancreas cancer
  • mRNA
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntarily signed the form and complied with protocols requirements
  • Patients with radiographically resectable primary pancreatic tumors
  • Histopathology or cytology confirmed resected PDAC with macroscopic complete resection (R0 and R1)
  • Pancreatic cancer surgical staging per AJCC 8th edition staging: T 1-3, N0-2, M0
  • 0 or 1
  • ≥ 6 months
  • Surgical complications have recovered,
  • Adequate organ function
  • Patients with fertility are willing to use an adequate method of .

Exclusion criteria

Exclusion Criteria:

  • The presence of other pathologic types
  • Participating in another clinical study
  • Have received treatment for pancreatic cancer, including chemotherapy, radiation therapy, targeted therapy, immunotherapy,etc
  • Plan to receive a within 28 days prior to initiation of study treatment or during the study treatment or within 90 days after the end of study treatment
  • Severe infection occurs within 4 weeks prior to the first dose
  • Requiring systemic therapy with or other drugs within 14 days prior to initial administration.
  • Acute pancreatitis or subclinical pancreatitis
  • Active disease
  • Allergic to immunotherapies and related drugs
  • History of allogeneic organ transplantation or hematopoietic stem cell transplantation.
  • Splenectomy history
  • Active tuberculosis
  • Known or highly suspected history of interstitial pneumonia.
  • liver disease
  • Uncontrolled or severe cardiovascular disease.
  • Severe bleeding tendency or history of coagulopathy
  • Active within the last 3 years
  • Active syphilis infection
  • Any other situations that are not suitable for inclusion in this study judged by investigator.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Pancreatic Cancer

    Resectable PDAC

    Biological: AK154 · Biological: Cadonilimab · Biological: Ivonescimab (SMT112 or AK112) Injection · Drug: mFOLFORINOX

Interventions

  • BiologicalAK154

    AK154 is neotigeon personalized mRNA vaccine

  • BiologicalCadonilimab

    a PD-1/CTLA-4 bispecific antibody

  • a PD-1/VEGF bi-specific antibody

  • DrugmFOLFORINOX

    mFOLFIRINOX:Fluorouracil+leucovorin+Irinotecan+Oxaliplatin

06

What researchers measure

Primary outcomes

  1. DLT

    Percentage of subjects who meet the criteria of DLT in DLT observation period

    Time frame: Day 1 to Day 21 after the first tumour vaccine was administrated

  2. AE

    Percentage of subjects with Adverse Events (AEs)

    Time frame: From ICF up to 30days after last study treatment

Secondary outcomes

  1. RFS

    Recurrence free survival(RFS)

    Time frame: 2 years

  2. OS

    Overall survival(OS)

    Time frame: 2 years

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2025; primary completion for Feb 2028, 31 months later.

Of 172 industry-sponsored phase 1 interventional studies under Pancreatic Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 62. This study's planned 31 months is below that.

Counting every sponsor, half of 381 studies reached it within 45 months; a quarter within 32 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2025
First posted
Apr 6, 2025
StartEst.
Jul 22, 2025
Primary completionEst.
Feb 23, 2028
CompletionEst.
Nov 6, 2028
Last update
Apr 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06913218
Lead sponsor
Akeso
Collaborators
Fudan University Shanghai Cancer Center ( FUSCC )
Responsible party
Sponsor
First posted
Apr 6, 2025
Start date
Jul 22, 2025 (estimated)
Primary completion
Feb 23, 2028 (estimated)
Completion
Nov 6, 2028 (estimated)
Last update
Apr 6, 2025

Study contacts

Ting Liu
Contact
clinicaltrials@akesobio.com
+86 (0760) 8987 3999

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion